Liminatus Pharma, Inc. (LIMN)
NASDAQ: LIMN · Real-Time Price · USD
6.74
-0.46 (-6.34%)
Jul 11, 2025, 1:46 PM - Market open
Company Description
Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies.
It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPα blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis.
The company was founded in 2018 is based in LA Palma, California.
Liminatus Pharma, Inc.
Country | United States |
Founded | 2018 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Chris Kim |
Contact Details
Address: 6 Centerpointe Drive, #625 La Palma, California 90623 United States | |
Phone | 213 273 5453 |
Website | liminatuspharma.com |
Stock Details
Ticker Symbol | LIMN |
Exchange | NASDAQ |
Stock Type | Common Stock |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001831874 |
ISIN Number | US53271X1081 |
Key Executives
Name | Position |
---|---|
Chris Kim J.D., L.L.M. | Chief Executive Officer, Treasurer and Secretary |